We thank O'Connor and Fraser for their comments, which suggest a diff ering association between early and late hyperlactatemia and mortality in post-operative cardiac surgery patients and that the inclusion of this cohort in our 'cardiac/vascular' group may have weakened the association between lactate and mortality in our study.
We thank O'Connor and Fraser for their comments, which suggest a diff ering association between early and late hyperlactatemia and mortality in post-operative cardiac surgery patients and that the inclusion of this cohort in our 'cardiac/vascular' group may have weakened the association between lactate and mortality in our study.
Th ey are correct in assuming that a signifi cant number of patients from the 'cardiac/vascular' group were postoperative cardiac patients, as three of the four intensive care units in our study support busy cardiothoracic services. Unfortunately, the coding of our database prevents us from identifying these patients in more detail. However, we were able to separate and examine the cardiac/vascular group, the surgical group, and the cardiac/vascular patients who underwent surgery. In the cardiac/vascular surgical group, the risk of death was increased with hyperlactatemia compared with all of the other groups (Table 1 ). In addition, the risk of death determined by maximal and time-weighted lactate (more strongly refl ecting post-admission lactate levels) was greater in the cardiac/vascular surgical group compared with the other groups ( Table 1) .
Th ese fi ndings demonstrate that early (admission) and late (post-admission) hyperlactatemia are both strongly associated with mortality in cardiac/vascular surgical patients (of whom a signifi cant number were postoperative cardiac patients). Th is would suggest that the inclusion of cardiac surgical patients did not weaken the association with mortality; it actually strengthened the overall association. Th ese fi ndings demand more study of lactate in the cardiac surgical cohort, and we eagerly await the publication of the results alluded to by O'Connor and Fraser.
We read with interest the article by Nichol and colleagues [1] in a recent issue of Critical Care. Th eir study of more than 7,000 medical and surgical patients supports the claim that an admission plasma lactate level in the upper normal range is associated with increased mortality. However, we are concerned about the lack of data regarding patient baseline characteristics. Specifi cally, although 3,166 and 1,614 patients had diagnoses of 'surgery' and 'cardiac/vascular' , respectively, it is likely, but not stated, that numerous patients were admitted following cardiac surgery. Th is is of great importance as changes in lactate in this patient group are not homogenous in nature.
In post-cardiac surgery patients, early hyperlactatemia and late hyperlactatemia (LHL) diff er in both risk profi le and physiological rationale. Early hyperlactatemia (on intensive care unit arrival) is associated with adverse outcome. Th is association is not seen in the 10% to 20% of patients who develop LHL (pooled odds ratio [OR] of death with LHL in two published trials 1.39, 95% confi dence interval [CI] 0.28 to 7.04) [2] [3] [4] . Moreover, in our recent single-center review of prospectively collated data from 529 post-cardiac surgical patients in a tertiary Australian cardiac surgical intensive care unit, 25% developed LHL (>2.5 mmol/L). When compared with patients with a normal lactate profi le, patients with LHL showed no increase in hospital mortality (OR 0.57, 95% CI 0.07 to 5.05) (unpublished data).
Th erefore, we believe that inclusion of such patients in studies of lactate in critical illness should be avoided and, as in the study by Nichol and colleagues, may actually weaken any association demonstrated between lactate levels and hospital mortality. 
